Cloud infrastructures for in silico drug discovery: economic and practical aspects.
Cloud computing opens new perspectives for small-medium biotechnology laboratories that need to perform bioinformatics analysis in a flexible and effective way. This seems particularly true for hybrid clouds that couple the scalability offered by generalpurpose public clouds with the greater control...
| Publicado en: | BioMed Research International Vol. 2013; pp. 138012 - 138013 |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Wiley-Blackwell
2013
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104104951&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104104951 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 2013 vid: 2013 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 104104951 2012341075 NLM24106693 PMC3782806 104104951 ppf: 138012 ppct: 1 formats: fmt: @attributes: type: P tig: atl: Cloud infrastructures for in silico drug discovery: economic and practical aspects. aug: au: D'Agostino, Daniele Clematis, Andrea Quarati, Alfonso Cesini, Daniele Chiappori, Federica Milanesi, Luciano Merelli, Ivan affil: Institute of Applied Mathematics and Information Technologies, National Research Council of Italy, via de Marini 6, 16149 Genoa, Italy. sug: subj: Computer Simulation Computing Methodologies Drug Discovery Biotechnology ab: Cloud computing opens new perspectives for small-medium biotechnology laboratories that need to perform bioinformatics analysis in a flexible and effective way. This seems particularly true for hybrid clouds that couple the scalability offered by generalpurpose public clouds with the greater control and ad hoc customizations supplied by the private ones. A hybrid cloud broker, acting as an intermediary between users and public providers, can support customers in the selection of the most suitable offers, optionally adding the provisioning of dedicated services with higher levels of quality. This paper analyses some economic and practical aspects of exploiting cloud computing in a real research scenario for the in silico drug discovery in terms of requirements, costs, and computational load based on the number of expected users. In particular, our work is aimed at supporting both the researchers and the cloud broker delivering an IaaS cloud infrastructure for biotechnology laboratories exposing different levels of nonfunctional requirements. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|